Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$380 Mln
Revenue (TTM)
$22 Mln
Net Profit (TTM)
$-33 Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4.7
Industry P/E
24.51
EV/EBITDA
-4.5
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$--
EPS
$7.1
Face value
--
Shares outstanding
22,761,000
CFO
$-731.40 Mln
EBITDA
$-647.36 Mln
Net Profit
$-721.88 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
| 1.5 | 1.5 | 5.0 | 193.0 | -34.6 | -33.5 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
| 343.4 | -72.0 | -69.4 | -68.6 | -12.6 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
16.7 | 380.1 | 21.8 | 69.9 | -467.1 | 76.8 | -- | 4.7 |
| 0.5 | 35.4 | 0.0 | -28.2 | -- | -58.1 | -- | 0.8 |
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell... gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. As of January 24, 2024, Orchard Therapeutics plc operates as a subsidiary of Kyowa Kirin Co., Ltd.. Read more
CEO, Member of Scientific Advisory Board & Executive Director
Dr. Hubert Baburaj Gaspar M.D., Ph.D.
CEO, Member of Scientific Advisory Board & Executive Director
Dr. Hubert Baburaj Gaspar M.D., Ph.D.
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Orchard Therapeutics plc - ADR is $16.70 (NASDAQ) as of 02-Feb-2024 09:30 EDT. Orchard Therapeutics plc - ADR has given a return of -34.64% in the last 3 years.
Since, TTM earnings of Orchard Therapeutics plc - ADR is negative, P/E ratio is not available.
The P/B ratio of Orchard Therapeutics plc - ADR is 4.74 times as on 05-Feb-2024, a 16 discount to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.60
|
0.05
|
|
2021
|
-0.46
|
0.08
|
|
2020
|
-0.28
|
0.24
|
|
2019
|
-0.83
|
0.45
|
|
2018
|
-0.59
|
0.43
|
The 52-week high and low of Orchard Therapeutics plc - ADR are Rs -- and Rs -- as of 05-Apr-2026.
Orchard Therapeutics plc - ADR has a market capitalisation of $ 380 Mln as on 05-Feb-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Orchard Therapeutics plc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.